Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis

INTRODUCTION: Ertugliflozin is a new sodium-glucose co-transporter-2 inhibitor (SGLT2i) for the treatment of type 2 diabetes mellitus. As there are no head-to-head trials comparing the efficacy of SGLT2is, the primary objective of this analysis was to indirectly compare ertugliflozin to other SGLT2i...

Descripción completa

Detalles Bibliográficos
Autores principales: McNeill, Ann M., Davies, Glenn, Kruger, Eliza, Kowal, Stacey, Reason, Tim, Ejzykowicz, Flavia, Hannachi, Hakima, Cater, Nilo, McLeod, Euan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437246/
https://www.ncbi.nlm.nih.gov/pubmed/30689140
http://dx.doi.org/10.1007/s13300-019-0566-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437246/
https://www.ncbi.nlm.nih.gov/pubmed/30689140
http://dx.doi.org/10.1007/s13300-019-0566-x

Ejemplares similares